Dr. Antoni Chan synovialjoints
2 years 4 months ago
This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the detection of joint inflammation, compared to joint ultrasound showed excellent performance in the differentiation of joints with US inflammatory activity from… https://t.co/1unRxxgHAd https://t.co/tOPDSxzvwB
David Liew drdavidliew
2 years 4 months ago
Does TCZ switch off GCA histopathologically?
GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat)
Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary
#EULAR2024 OP0233 Reggio Emilia @RheumNow https://t.co/TKBUP5p4R0
Dr. John Cush RheumNow
2 years 4 months ago
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our faculty.
Dr. John Cush RheumNow
2 years 4 months ago
Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T
Bella Mehta bella_mehta
2 years 4 months ago
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 !
Amazing pictures to explain cellular level pathophysiology!
Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 4 months ago
#EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ
Janet Pope Janetbirdope
2 years 4 months ago
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
PA Juge Juge_P_A
2 years 4 months ago
Oral presentation at #EULAR2024 about clustering #RA #ILD 🫁 @PhilippeDieude @jeffsparks @RaphaelBorie @bruno_crestani https://t.co/jz1unKIZmN
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Do the clinical features of axSpA patients with and without IBD differ?
In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.
Dr. John Cush RheumNow
2 years 4 months ago
Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
Annals of the Rheumatic Diseases ARD_BMJ
2 years 4 months ago
New hypothesis are explored in #Sjogren
#EULAR2024
CB https://t.co/0glF5BGVO5
